MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ndt/gfn296

Медицинская библиотека · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2008

Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.

Seiler Sarah, Schlitt Axel, Jiang Xian-Cheng, Ulrich Christof, Blankenberg Stefan, Lackner Karl J, Girndt Matthias, Werdan Karl, Buerke Michael, Fliser Danilo, Heine Gunnar H

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Patients with chronic kidney disease (CKD) have an increased risk for cardiovascular events (CVE). Uraemic dyslipidaemia, which is characterized by low HDL-cholesterol (HDL-C) and elevated triglycerides' levels, may contribute to this elevated cardiovascular risk. Cholesteryl ester transfer protein (CETP) lowers HDL-C by transferring cholesterol esters to LDL and VLDL particles. We tested the hypothesis that CETP activity is associated with CVE in patients with CKD stage V.

METHODS

We measured CETP activity and cholesterol levels in 69 haemodialysis patients. CVE and death were prospectively assessed over a follow-up period of 48 months.

RESULTS

CETP activity was negatively correlated with HDL-C levels in patients without lipid-lowering medication (r = -0.379, P = 0.005). We found no difference in CETP activity in patients with cardiovascular disease at baseline compared to patients without cardiovascular disease. The same was true for incident CVE during the follow-up. When stratifying patients by median CETP activity, patients with high CETP activity did not have an increased risk for CVE (P = 0.901 by the log-rank test) or death (P = 0.615). Similarly, after stratifying patients by median HDL-C no increased risk for CVE (P = 0.780) or death (P = 0.838) was found in patients with low HDL-C.

CONCLUSIONS

In summary, although CETP activity correlated with HDL-C levels, neither high CETP activity nor low HDL-C was associated with CVE in CKD stage V patients. Thus, pharmacological modification of HDL-C by CETP inhibitors seems to be of questionable value in these patients.

Для цитирования: Seiler Sarah, Schlitt Axel, Jiang Xian-Cheng, Ulrich Christof, Blankenberg Stefan, Lackner Karl J, Girndt Matthias, Werdan Karl, Buerke Michael, Fliser Danilo, Heine Gunnar H. Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2008. DOI: 10.1093/ndt/gfn296.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.